Michael Murawsky1, Gary R Kelm1, Darby Kozak2, Bin Qin2, Yuan Zou2, S Kevin Li1. 1. a Division of Pharmaceutical Sciences , James L Winkle College of Pharmacy, University of Cincinnati , Cincinnati , OH , USA. 2. b Office of Research and Standards, Office of Generic Drugs, U.S. Food and Drug Administration , Silver Spring , MD , USA.
Abstract
OBJECTIVE: The objective was to evaluate the influencing factors in the fabrication of gelatin matrix (gelatin chips) for drug delivery. The attributes affecting drug release characteristics of the gelatin products were examined. SIGNIFICANCE: Understanding the attributes that affect drug release from gelatin matrix could provide the knowledge base for the development, manufacturing, and performance evaluation of gelatin-based drug products for sustained drug delivery. METHODS: Chlorhexidine (CHX) was the model drug in the gelatin-product testing. The gelatin products were fabricated by two methods: a single-pot mixing of all the components and a two-step gelatin crosslinking followed by drug loading. Different gelatin types (Type A porcine and Type B bovine), glutaraldehyde (GTA) crosslinking conditions, glycerin concentration, and CHX concentration in drug loading and loading time were used to fabricate the products. The cumulative amounts of CHX release from the gelatin products were determined using in vitro release testing (IVRT). RESULTS: The attributes affecting CHX release from the gelatin products were gelatin type, GTA crosslinking, and CHX loading concentration. The fabrication methods (two-step method of gelatin crosslinking and drug loading by equilibration vs. direct mixing of the components) also affected CHX release. Other attributes such as glycerin and CHX loading time did not show significant effects on drug release under the conditions studied. In addition, the results in the two IVRT methods employed in this study were comparable. CONCLUSION: Gelatin products of qualitative (Q1) and quantitative (Q2) differences could lead to different drug release behaviors. Drug release was also affected by the ingredient mixing steps during gelatin chip fabrication.
OBJECTIVE: The objective was to evaluate the influencing factors in the fabrication of gelatin matrix (gelatin chips) for drug delivery. The attributes affecting drug release characteristics of the gelatin products were examined. SIGNIFICANCE: Understanding the attributes that affect drug release from gelatin matrix could provide the knowledge base for the development, manufacturing, and performance evaluation of gelatin-based drug products for sustained drug delivery. METHODS:Chlorhexidine (CHX) was the model drug in the gelatin-product testing. The gelatin products were fabricated by two methods: a single-pot mixing of all the components and a two-step gelatin crosslinking followed by drug loading. Different gelatin types (Type A porcine and Type B bovine), glutaraldehyde (GTA) crosslinking conditions, glycerin concentration, and CHX concentration in drug loading and loading time were used to fabricate the products. The cumulative amounts of CHX release from the gelatin products were determined using in vitro release testing (IVRT). RESULTS: The attributes affecting CHX release from the gelatin products were gelatin type, GTA crosslinking, and CHX loading concentration. The fabrication methods (two-step method of gelatin crosslinking and drug loading by equilibration vs. direct mixing of the components) also affected CHX release. Other attributes such as glycerin and CHX loading time did not show significant effects on drug release under the conditions studied. In addition, the results in the two IVRT methods employed in this study were comparable. CONCLUSION: Gelatin products of qualitative (Q1) and quantitative (Q2) differences could lead to different drug release behaviors. Drug release was also affected by the ingredient mixing steps during gelatin chip fabrication.
Entities:
Keywords:
release testing (IVRT); Gelatin; Q1 and Q2 equivalence; chlorhexidine; dissolution study; drug release
Authors: Paul A Dickinson; Wang Wang Lee; Paul W Stott; Andy I Townsend; John P Smart; Parviz Ghahramani; Tracey Hammett; Linda Billett; Sheena Behn; Ryan C Gibb; Bertil Abrahamsson Journal: AAPS J Date: 2008-08-07 Impact factor: 4.009
Authors: Igor E Shohin; Julia I Kulinich; Galina V Ramenskaya; Bertil Abrahamsson; Sabine Kopp; Peter Langguth; James E Polli; Vinod P Shah; D W Groot; Dirk M Barends; Jennifer B Dressman Journal: J Pharm Sci Date: 2012-07-11 Impact factor: 3.534
Authors: Anita Nair; Bertil Abrahamsson; Dirk M Barends; D W Groot; Sabine Kopp; James E Polli; Vinod P Shah; Jennifer B Dressman Journal: J Pharm Sci Date: 2012-09-04 Impact factor: 3.534